Macrophage Pharma Ltd has appointed Søren Bregenholt as chief executive officer to guide development of its small molecule drugs for cancer that work by inducing transcriptional reprofiling of macrophages. Dr Bregenholt was previously chief operating officer at Symphogen A/S as well as an executive of Novo Nordisk A/S. He obtained his academic qualifications from the University of Copenhagen in Denmark and Institute Pasteur in France.
Macrophage Pharma announced the appointment on 3 September 2019.
Copyright 2019 Evernow Publishing Ltd